A

Alnylam Pharmaceuticals

Develops RNAi-based therapies for genetic diseases

Principal Scientist - Biotransformation and Metabolite Profiling

Translational Research & Bench BiologyConfirmed live in the last 24 hours
Full-timeUnited StatesNo salary listed

About the Job

Requirements

  • A PhD in analytical chemistry, medicinal chemistry, pharmaceutical sciences, biochemistry, or drug metabolism, plus 6 or more years of relevant industry research experience in small molecule, peptide, oligonucleotide, or RNAi development.
  • Extensive hands-on experience in drug metabolism, metabolite profiling, and metabolite identification for small molecules, peptides, oligonucleotides, ADCs, or RNAi compounds.
  • Strong expertise in liquid chromatography–tandem mass spectrometry (LC-MS/MS) and high-resolution mass spectrometry, including interpretation of complex tandem mass spectrometry fragmentation data.
  • Ability to elucidate metabolite structures and construct scientifically supported biotransformation pathways.
  • Strong understanding of drug metabolism, pharmacokinetics, tissue distribution, and mechanisms governing metabolite formation.
  • Track record in preparing conference presentations, publications in peer-reviewed journals, or industry and regulatory white papers.
  • Ability to handle multiple projects in a fast-paced, team-oriented environment.
  • Verbal and written communication skills.

Responsibilities

  • Lead metabolite profiling and structural identification in plasma, urine, bile, tissues, and relevant in vitro biological matrices.
  • Support small molecules, peptides, RNAi, conjugated therapeutics, and other emerging therapeutic modalities.
  • Apply liquid chromatography–high-resolution tandem mass spectrometry approaches for metabolite detection, profiling, structural elucidation, and relative quantitation.
  • Conduct advanced mass spectrometry data processing using Thermo Scientific Compound Discoverer, BioPharma Finder, ProMass, Mass MetaSite, and other metabolite profiling software.
  • Design biotransformation strategies using hepatocytes, liver subcellular fractions, lysosomal systems, serum or plasma, tissue preparations, and other fit-for-purpose models.
  • Characterize metabolic pathways, including oxidation, reduction, hydrolysis, conjugation, proteolysis, deconjugation, linker cleavage, and other modality-specific catabolic pathways.
  • Support pharmacokinetic and pharmacodynamic analysis as needed.
  • Establish relationships between in vitro metabolism, in vivo circulating metabolites, and tissue-specific metabolism and catabolism.
  • Identify major, disproportionate, persistent, or pharmacologically relevant metabolites and interpret their potential significance.
  • Interpret accurate mass, isotope patterns, charge states, tandem mass spectrometry fragmentation, product-ion spectra, and chromatographic behavior to support metabolite assignments.
  • Evaluate and implement new mass spectrometry technologies, software, and data-processing approaches to improve metabolite identification efficiency and confidence.
  • Conduct non-GLP sample analysis supporting RNAi therapeutic development from development candidate selection and CTA/IND-enabling work through later stages.
  • Coach staff and support their career development, set goals, and conduct performance evaluations.
  • Interact with research, eDEV, and clinical teams for assigned programs, build working relationships, and serve as the bioanalytical representative for those programs.
  • Collaborate with cross-functional Research and Development teams to align projects and timelines and interpret data.
  • Author bioanalytical reports for in vitro and in vivo metabolite profiling used in IND filings and support method transfers to contract research organizations as needed.

About the Company

Alnylam Pharmaceuticals

Develops RNAi-based therapies for genetic diseases

Alnylam Pharmaceuticals develops RNA interference (RNAi) therapeutics to silence disease-causing genes, aiming to treat rare genetic disorders. Its products work by using RNA molecules that block gene expression, reducing the impact of specific genetic diseases. The company differentiates itself by concentrating on RNAi-based drugs for rare diseases and by building a pipeline through large clinical programs and strategic partnerships, such as commercialization deals in the Gulf States and collaborations with investors. Revenue comes from approved drug sales, licensing agreements, strategic collaborations, and related services like genetic testing and counseling. The company’s goal is to advance and commercialize RNAi therapies to improve outcomes for patients with genetic disorders, expanding its portfolio through partnerships and investments.

Company size
1,001-5,000
Company stage
IPO
Headquarters
Cambridge, MA
Founded
2002

Recently Posted Jobs

Explore more opportunities at Alnylam Pharmaceuticals

See more jobs